Intravenous pulse methylprednisolone in the treatment of uveitis associated with multiple sclerosis

Clin Exp Ophthalmol. 2000 Apr;28(2):103-6. doi: 10.1046/j.1442-9071.2000.00282.x.


Purpose: To demonstrate the safety and effectiveness of intravenous methylprednisolone (IVMP) in the treatment of uveitis in association with multiple sclerosis (MS).

Methods: Uveitis is an unusual manifestation of MS that may be severe, chronic and require systemic immunosuppression therapy. High-dose IVMP has previously been shown to be effective in the treatment of inflammatory eye disease and MS. Eight episodes of uveitis in five patients with MS were treated over a 10-year period in an open, uncontrolled trial. Two patients had chronic anterior uveitis, one patient had bilateral panuveitis and two patients had intermediate uveitis.

Results: All patients responded to IVMP with evidence of a decrease in intraocular inflammatory activity and improved visual acuity (VA) within 2 weeks of commencing treatment. There were no severe ocular or systemic steroid side effects.

Conclusions: Intravenous methylprednisolone is an effective, well-tolerated form of therapy for uveitis in patients with MS.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Adult
  • Female
  • Glucocorticoids / administration & dosage*
  • Humans
  • Injections, Intravenous
  • Methylprednisolone / administration & dosage*
  • Multiple Sclerosis / complications*
  • Safety
  • Uveitis, Anterior / drug therapy*
  • Uveitis, Anterior / etiology
  • Uveitis, Intermediate / drug therapy*
  • Uveitis, Intermediate / etiology
  • Uveitis, Posterior / drug therapy*
  • Uveitis, Posterior / etiology
  • Visual Acuity


  • Glucocorticoids
  • Methylprednisolone